These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9251067)

  • 1. Sleep benefit in Parkinson's disease.
    Merello M; Hughes A; Colosimo C; Hoffman M; Starkstein S; Leiguarda R
    Mov Disord; 1997 Jul; 12(4):506-8. PubMed ID: 9251067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
    Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
    Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E; González M; Aguilar A; Quintana S
    Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleepiness in Parkinson's disease: a controlled study.
    Brodsky MA; Godbold J; Roth T; Olanow CW
    Mov Disord; 2003 Jun; 18(6):668-72. PubMed ID: 12784270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleep disorders in Parkinson's disease.
    Kumar S; Bhatia M; Behari M
    Mov Disord; 2002 Jul; 17(4):775-81. PubMed ID: 12210875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations.
    Whitehead DL; Davies AD; Playfer JR; Turnbull CJ
    Mov Disord; 2008 Jun; 23(8):1137-45. PubMed ID: 18442142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
    Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nighttime sleep problems and daytime sleepiness in Parkinson's disease.
    Verbaan D; van Rooden SM; Visser M; Marinus J; van Hilten JJ
    Mov Disord; 2008 Jan; 23(1):35-41. PubMed ID: 17960797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the motor response to acute L-dopa challenge after unilateral microelectrode-guided posteroventral pallidotomy.
    Merello M; Nouzeilles MI; Cammarotta A; Pikielny R; Leiguarda R
    Clin Neuropharmacol; 1998; 21(2):135-8. PubMed ID: 9579303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
    Gómez-Esteban JC; Zarranz JJ; Lezcano E; Velasco F; Ciordia R; Rouco I; Losada J; Bilbao I
    Mov Disord; 2006 Jul; 21(7):983-8. PubMed ID: 16602112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep disorders and sleep effect in Parkinson's disease.
    Factor SA; McAlarney T; Sanchez-Ramos JR; Weiner WJ
    Mov Disord; 1990; 5(4):280-5. PubMed ID: 2259351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
    Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease.
    Degirmenci B; Yaman M; Haktanir A; Albayrak R; Acar M; Caliskan G
    Neurosci Lett; 2007 Apr; 416(3):294-8. PubMed ID: 17317000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances.
    Wetter TC; Trenkwalder C; Gershanik O; Högl B
    Wien Klin Wochenschr; 2001 Apr; 113(7-8):249-53. PubMed ID: 11383385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.